Overview

PARP Inhibitors Market is poised to value USD 10417.90 million by 2028 end at a CAGR of 11.2% during the forecast period 2022 to 2028.

Increasing prevalence of cancer, rising acceptance of PARP inhibitors drugs, increased geriatric population and scientific advancements in the healthcare sector across the world are some of the kay factors contributing to the growth of the market. Moreover, the key market players are introducing novel techniques for developing advanced cancer treatments which shall propel the PARP inhibitors market growth. On the other hand, strict governmental regulations and frequent product recalls are predicted to impede the market growth substantially in the upcoming years. 
For many years, cancer has been the leading cause of death across the world. As per the WHO, cancer is the reason for over 8 million deaths each year, with over 65% new cancer cases are anticipated to be registered over the next two decades. Rising population afflicted with cancer shall prove to be a key factor in the augmentation of the market. As per the data provided by the CDC, 2014, the number of cancer patients reached over 20 million in the United States and it is estimated that this number shall reach over 25 million by 2024 end. Additionally, the rising geriatric population getting diagnosed with cancer shall propel the growth of the market. As per the Administration for Community Living, the number of people over the age of 65 in the United States were over 46 million in 2014.

Market Segmentation:

By Drug Type
•    Lynaprza
•    Niraparib
•    Rucaparib
•    Talazoparib
•    Veliparib 
•    Others    
By Indication
•    Ovarian Cancer
•    Breast Cancer
•    Prostate Cancer
•    Pancreatic Cancer
•    Lung Cancer
•    Others
By Distribution channel 
•    Hospital Pharmacies
•    Retail Pharmacies
•    Online Pharmacies
•    Others
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is classified into drug type, indication, distribution channel and region. The drug type segment is diversified into lynaprza, niraparib, rucaparib, talazoparib, veliparib and others. The indication segment is fragmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, lung cancer and others. The distribution channel segment is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies and others.

Regional Analysis:

The North America region is expected to lead the market during the forecast period owing to the rising geriatric population, increased prevalence of cancer owing to unhealthy lifestyle and dietary choices and a strong presence of key market players in the region.

Competitive Landscape:                            

Some of the major market players associated are AstraZeneca, Tesaro, AbbVie Inc., Medivation, Clovis Oncology. AstraZeneca is primarily engaged in manufacturing, discovery, commercialization, distribution of biopharma products. It provides different services in therapeutics for metabolic and cardiovascular diseases, respiratory, oncological, autoimmunity and inflammation. 

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global PARP inhibitors market by drug type, by indication, by distribution channel and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions            

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. PARP Inhibitors Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of PARP Inhibitors Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. PARP Inhibitors Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. PARP Inhibitors Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Lynaprza
   7.2. Niraparib
   7.3. Rucaparib
   7.4. Talazoparib
   7.5. Veliparib 
   7.6. Others       

8. PARP Inhibitors Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Ovarian Cancer
   8.2. Breast Cancer
   8.3. Prostate Cancer
   8.4. Pancreatic Cancer
   8.5. Lung Cancer
   8.6. Others   

9. PARP Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospital Pharmacies
   9.2. Retail Pharmacies
   9.3. Online Pharmacies
   9.4. Others

10. North America PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. AstraZeneca
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Tesaro 
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. AbbVie Inc.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Medivation
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Clovis Oncology
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures